Quarterly report [Sections 13 or 15(d)]

Segment Information - Schedule of Reconciliation to the Consolidated Net Loss (Details)

v3.26.1
Segment Information - Schedule of Reconciliation to the Consolidated Net Loss (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Reconciliation of net loss    
Change in fair value of warrant liabilities $ 1,542,132 $ 76,867
Realized foreign currency translation loss from dissolution of subsidiaries (7,171)
Foreign currency gain/(loss) (9,491)
Other income   7,000
Interest and dividends, net 450,338 47,245
Segment and consolidated net loss (2,869,482) (3,563,238)
Reporting Segment [Member]    
Schedule of Reconciliation to the Consolidated Net Loss [Line Items]    
General and administrative [1] 1,640,086 1,696,425
Pre-clinical research [1] 374,361 61,993
CMC [1] 658,398 224,597
Clinical development [1] 1,907,076 1,434,804
Depreciation and amortization 157,541 161,708
Share based compensation expense 139,182 98,558
Other segment items [2] 2,094
Total operating and segment expenses 4,876,644 3,680,179
Reconciliation of net loss    
Change in fair value of warrant liabilities 1,542,132 76,867
Realized foreign currency translation loss from dissolution of subsidiaries (7,171)
Foreign currency gain/(loss) (9,491)
Other income 24,183
Change in fair value of derivative warrant liability
Interest and dividends, net 450,338 47,245
Segment and consolidated net loss $ (2,007,162) $ (3,563,238)
[1] includes personnel costs and excludes share-based compensation expense and impairment expense
[2] includes litigation settlements, loss from sale of assets, and loss on asset write offs